Lung Cancer | Clinical

November 25, 2021

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

November 23, 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

November 23, 2021

Jyoti Patel, MD, and Karen Reckamp, MD, discuss strategies for identifying ALK rearrangements in patients with advanced NSCLC and which patients should be tested for these alterations.

November 23, 2021

Karen Reckamp, MD, provides an overview of ALK gene rearrangements and their clinical significance in patients with advanced NSCLC.

November 23, 2021

From scientists to oncologists and other clinicians in the community setting, years of research has grasped the big picture of lung cancer occurrence and outcomes in Kentucky, and some have begun to investigate potential causes.

November 22, 2021

Ensartinib, an investigational ALK inhibitor, significantly extended progression-free survival versus crizotinib in patients with advanced disease in the phase 3 eXalt3 randomized clinical trial.

November 21, 2021

Nino Balanchivadze, MD, FACP, discuses the rates of acute kidney injury in the KEYNOTE-189 study, which evaluated pembrolizumab and carboplatin/pemetrexed in patients with metastatic non–small cell lung cancer.

November 19, 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

November 18, 2021

The FDA has granted fast track designation to MT-6402 for the treatment of patients with advanced non–small cell lung cancer expressing PD-1.

November 17, 2021

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.